Edesa Biotech, Inc. (NASDAQ:EDSA) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common shares (or pre-funded warrants) and accompanying common share warrants Announced: about US$25M · US$5.5 a share · Warrants at US$7.5 · Guggenheim Securities Dealers: Guggenheim Securities (lead) Use of proceeds: General corporate purposes, possibly including working capital, capital expenditures, and research, development and manufacturing expenses | Aug 20, 2026 |
| Private placement of common shares Announced: about US$3.5M · US$4.69 a share Buyers: Chief Executive Officer of Edesa (common shares at $5.21 per common share) Insiders: Edesa's Chief Executive Officer is an investor in the PIPE, buying at $5.21 per common share Use of proceeds: Advancing the vitiligo program and paridiprubart, plus working capital and general corporate purposes | Jun 11, 2026 |
| At-the-market programme of common shares Tranche closed: US$3.4M raised | Dec 12, 2025 |
| Private placement of series B-1 convertible preferred shares and common shares Closed: US$15M raised · US$1.92 a share Buyers: Velan Capital (led the placement); Nantahala Capital; Rubric Capital Management LP; Stonepine Capital Management; Broadfin Holdings LLC Insiders: Officers and directors purchased approximately $1.1 million of the securities sold Use of proceeds: Advance EB06 CXCL10 antibody into a Phase 2 study in nonsegmental vitiligo, plus working capital and general corporate purposes | Feb 13, 2025 |
| Private placement of securities Closed: US$1.5M raised Buyers: Entity affiliated with Edesa's Chief Executive Officer and Founder ($1.5 million in gross proceeds under a securities purchase agreement) Insiders: An entity affiliated with the Chief Executive Officer and Founder provided the $1.5 million under a securities purchase agreement | Dec 13, 2024 |
| At-the-market programme of common shares Tranche closed: US$600,000 raised | Dec 13, 2024 |